Lack of mRNA tech transfer “a blessing in disguise” for WHO vaccine team, says Afrigen boss
Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.